shining a light on Multiple Myeloma
Multiple myeloma is not a common cancer. This year, an estimated 34,920 adults (19,320 men and 15,600 women) in the United States will be diagnosed with multiple myeloma.
To expose the shadows of Multiple Myeloma through support and education to patients and caregivers.
A New CAR T Target in Multiple Myeloma: GPRC5D
The myeloma therapy arsenal is growing in number and new therapies are improving the life span of multiple myeloma patients. Examples of this include CAR-T therapy, monoclonal antibodies, bispecific agents, and antibody drug conjugates. Dr. Fredrik Schjesvold, founder and leader of the Oslo Myeloma Center at Oslo University Hospital said these new advances are "really changing the disease.”
One of these new therapies is the MCARH109, a chimeric antigen receptor (CAR) modified T cells for the treatment of multiple myeloma that target GPRC5D (a protein receptor) in the myeloma cells.